Trial Profile
A Randomized, Placebo-controlled, Observer-blinded Phase 1 Study to Assess the Safety and Immunogenicity of Two Different Dose Levels of an Alum Adjuvanted Inactivated Whole Zika Virus Vaccine Candidate (VLA1601) in Healthy Flavivirus-naïve Adults Aged 18 to 49 Years
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 26 Feb 2019
Price :
$35
*
At a glance
- Drugs VLA-1601 (Primary)
- Indications Zika virus infection
- Focus Adverse reactions; First in man
- Sponsors Valneva
- 21 Feb 2019 According to a Valneva media release, the final analysis at day 208 after first vaccination, which is expected in the first half of 2019.
- 06 Dec 2018 Status changed from active, no longer recruiting to completed.
- 19 Nov 2018 According to an Emergent BioSolutions media release, the final analysis at day 208 after first vaccination is expected in the first quarter 2019.